Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
digestive system diseases | D004066 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
colorectal neoplasms | — | D015179 | — |
gastrointestinal stromal tumors | EFO_0000505 | D046152 | C49.A |
hepatocellular carcinoma | — | D006528 | C22.0 |
Expiration | Code | ||
---|---|---|---|
REGORAFENIB, STIVARGA, BAYER HLTHCARE | |||
2024-04-27 | ODE-139 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 23 | 57 | 16 | 3 | 21 | 103 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 3 | 12 | 2 | 1 | 5 | 21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 16 | 1 | — | 10 | 28 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 13 | 2 | — | 7 | 23 |
Glioblastoma | D005909 | EFO_0000515 | — | — | 3 | 1 | — | 2 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 20 | 13 | — | — | 2 | 30 |
Sarcoma | D012509 | — | — | 1 | 7 | — | — | — | 7 |
Rectal neoplasms | D012004 | — | — | 3 | 4 | — | — | — | 7 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 5 | — | — | 1 | 7 |
Adenocarcinoma | D000230 | — | — | 3 | 6 | — | — | — | 7 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 5 | — | — | — | 6 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 6 | — | — | — | 6 |
Colonic neoplasms | D003110 | — | C18 | 3 | 3 | — | — | — | 6 |
Osteosarcoma | D012516 | — | — | 1 | 5 | — | — | 1 | 6 |
Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 1 | — | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 1 | 2 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
Leiomyosarcoma | D007890 | — | — | — | — | — | — | 1 | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Drug common name | Regorafenib |
INN | regorafenib |
Description | Regorafenib is a pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It is an aromatic ether, a pyridinecarboxamide, a member of monochlorobenzenes, a member of (trifluoromethyl)benzenes, a member of monofluorobenzenes and a member of phenylureas. |
Classification | Small molecule |
Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1 |
PDB | — |
CAS-ID | 755037-03-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1946170 |
ChEBI ID | 68647 |
PubChem CID | 11167602 |
DrugBank | DB08896 |
UNII ID | 24T2A1DOYB (ChemIDplus, GSRS) |